Company intelligence / Profile preview

Hankook Shinyak

Nonsan, Chungcheongnam-do, South Korea

Ownership: Private
Development stage: Other

Overview

Hankook Shinyak manufactures more than 300 traditional herbal-based drugs, cosmetic products with botanical extracts, and achieved recognition for developing TAXOL (generic paclitaxel, an anti-cancer drug)[4][3]. MESIMA EX (Phellinus linteus mycelium extract) is marketed as an immunostimulant. No ongoing clinical trial data found; primarily commercial-stage herbal and natural products.

Therapeutic areas: ImmunologyOncology
Modalities: Traditional herbal extract drugsSmall moleculeNatural product extractBiologic
Industry: Biotech

Drug pipeline

6 assets

phellinus linteus mycelium

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

HERB OF EDEN CO. (Washington D.C.; export partner)MESIMA EX sales partnership (partly with DEXCO Trading Inc. as supplier)

Beyond the preview

Go deeper on Hankook Shinyak.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hankook Shinyak.

Explore the full profile